Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br medicine use among cancer

    2020-08-18


    medicine use among cancer survivors: A population-based study. J Cancer Surviv.
    11. Tao W, Luo X, Cui B, Liang D, Wang C, Duan Y. Practice of traditional Chinese medicine for psycho-behavioral intervention improves quality of life in cancer pa-tients: A systematic review and meta-analysis. Oncotarget. 2015;6(37):39725–39739.
    12. Yiu YM, Qiu MY. A preliminary epidemiological study and discussion on traditional Chinese medicine pathogenesis of chronic fatigue syndrome in Hong Kong. J Chin Integr Med. 2005;3(5):359–362.
    15. Wang Q. Classification and diagnosis basis of nine basic constitutions in Chinese medicine. J Beijing Univ Tradit Chin Med. 2005;28(4):1–8. 16. Sun Y, Zhao Y, Xue SA, Chen J. The theory development of traditional Chinese medicine constitution: A review. J Tradit Chin Med Sci. 2018;5:16–28. 17. Sun Y, Liu P, Zhao Y, et al. Characteristics of TCM constitutions of adult Chinese women in Hong Kong and identification of related influencing factors: A cross-sec-tional survey. J Transl Med. 2014;12:140.
    18. Chien TJ, Song YL, Lin CP, Hsu CH. The correlation of traditional chinese medicine deficiency syndromes, cancer related fatigue, and quality of life in breast cancer patients. J Tradit Complement Med. 2012;2(3):204–210.
    questionnaire to assess Yin-Xu. Part I: Establishment of a provisional version through a Delphi process. Forsch Komplementmed. 2012;19(5):234–241. 23. Lin JS, Chen LL, Lin JD, et al. BCQ-: A body constitution questionnaire to assess yin-
    28. Lin SJ, Cheng YY, Chang CH, Lee CH, Huang YC, Su YC. Traditional Chinese medi-cine diagnosis "yang-xu zheng": significant prognostic predictor for patients with severe sepsis and septic shock. Evid Based Complement Alternat Med. 2013;2013 759748.
    29. Tsai CI, Su YC, Lin SY, Lee I, Lee CH, Li TC. Reduced health-related quality of life in body constitutions of yin-xu, and yang-xu, stasis in patients with type 2 diabetes: taichung diabetic body constitution study. Evid Based Complement Alternat Med. 2014;2014 309403.
    30. Liang KL, Jiang RS, Lee CL, Chiang PJ, Lin JS, Su YC. Traditional Chinese medicine Zheng identification provides a novel stratification approach in patients with allergic rhinitis. Evid Based Complement Alternat Med. 2012;2012 480715.
    31. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between fatigue and inflammatory marker levels in cancer patients: A quantitative review. Brain Behav Immun. 2007;21(4):413–427.
    37. Yang K, Cai SC, Zhu CF, Fei AH, Qin XF, Xia JG. Clinical study on primary osteo-porosis treated with spreading moxibustion for warming yang and activating blood circulation. Chin Acupunct Moxibust. 2014;34(6):555–558. 38. Huang SM, Chien LY, Tai CJ, Chen PH, Lien PJ, Tai CJ. Effects of symptoms and complementary and alternative medicine use on the yang deficiency pattern among breast cancer patients receiving chemotherapy. Complement Ther Med. 2015;23(2):233–241.
    ORIGINAL ARTICLE
    Association of transcriptional levels of folate-mediated one-carbon metabolism-related Ferrostatin 1 in cancer cell lines with drug treatment response
    Dong-Joon Min1, Suleyman Vural1, Julia Krushkal∗ Computational and Systems Biology Branch, Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 9609 Medical Center Dr., Rockville, MD 20850, United States
    Abstract
    Folate-mediated one-carbon metabolism is essential for growth and survival of cancer cells. We investigated whether the response of cancer cells to antitumor treatment may be partially in-fluenced by variation in expression of one-carbon metabolism genes. We used cancer cell line in-formation from the Cancer Cell Line Encyclopedia and the Genomics of Drug Sensitivity in Cancer resources to examine whether variation in pretreatment expression of one-carbon metabolism-related genes was associated with response to treatment. GART, TYMS, SHMT2, MTR, ALDH2, BHMT, MAT2B, MTHFD2, NNMT, and SLC46A1 showed modest statistically significant correla-tions with response to a variety of antitumor agents. Higher expression levels of SLC46A1 were associated with resistance to multiple agents, whereas elevated expression of GART, TYMS, SHMT2, MTR, BHMT, and MAT2B was associated with chemosensitivity to multiple drugs. NNMT expression was bimodally distributed and showed different directions of association with various agents. Correlation of increased NNMT expression with sensitivity to dasatinib was validated in
    Abbreviations: 10-formylTHF, 10-formyltetrahydrofolate; 5,10-methylene-THF, 5,10-methylenethetrahydrofolate; AHCY, adenosylhomocys-teinase; ALDH1L1, aldehyde dehydrogenase 1 family, member L1; ALDH2, aldehyde dehydrogenase 2 family; ALK, anaplastic lymphoma kinase; ALL, acute lymphoblastic leukemia; AMT, aminomethyltransferase; ATF4, activating transcription factor 4; ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase; BHMT, betaine-homocysteine methyltransferase; CBS, cystathionine β-synthase; CCLE, Cancer Cell Line Encyclopedia; CTH, cystathionase; DDR1, discoidin domain receptor 1; DHF, dihydrofolate; DHFR, di-hydrofolate reductase; EDNRA, endothelin-1 receptor (endothelin receptor type A); EGFR, epidermal growth factor receptor; FDR, false discovery rate; FOLH1, folate hydrolase 1; FOLR1, folate receptor 1; FOLR2, folate receptor 2; FOLR3, folate receptor 3; FTCD, formimi-doyltransferase cyclodeaminase; GART, glycinamide ribonucleotide formyltransferase; GDSC, Genomics of Drug Sensitivity in Cancer; HDAC, histone deacetylase; HIF-1, hypoxia-inducible factor 1; LXR, liver X receptor; MAT1A, L-methionine S-adenosyltransferase 1, alpha; MAT2A, L-methionine S-adenosyltransferase 2, alpha; MAT2B, L-methionine S-adenosyltransferase 2, beta; MTHFD1, methylenetetrahydrofolate de-hydrogenase 1; MTHFD2, methylenetetrahydrofolate dehydrogenase 2; MTHFD2L, methylenetetrahydrofolate dehydrogenase 2-like; MTHFR, 5, 10-methylenetetrahydrafolate reductase; MTHFS, methylenetetrahydrofolate synthase; mTOR, mammalian target of rapamycin; MTR, me-thionine synthase; MTRR, 5-methyltetrahydrafolate-homocysteine methyltransferase reductase; NCI, National Cancer Institute; NNMT, nicoti-namide N-methyltransferase; OCM, one-carbon metabolism; OXPHOS, oxidative phosphorylation; PDK, pyruvate dehydrogenase kinase; PEMT, phosphatidylethanolamine-N-methyltransferase; PHGDH, phosphoglycerate dehydrogenase; PLK3, polo-like kinase 3; RIPK1, receptor-interacting serine/threonine-protein kinase 1; RMA, Robust Multiarray Average; ROS, reactive oxygen species; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; SHMT1, serine hydroxymethyl transferase 1; SHMT2, serine hydroxymethyl transferase 2; SLC19A1, solute car-rier family 19 member 1; SLC46A1, solute carrier family 46 member 1; TCA, tricarboxylic acid; TCN2, transcobalamin 2; THF, tetrahydrofolate; TYMS, thymidylate synthase; VEGFR, vascular endothelial growth factor receptor.